摘要
目的:为肿瘤患者安全使用表柔比星联合环磷酰胺治疗(即EC方案)提供参考。方法:临床药师参与1例罕见EC方案致CTCAE(common terminology criteria for adverse events,不良事件通用术语标准)评价为2级间质性肺病患者的救治,并检索PubMed、Elsevier Science Direct、中国知网、万方等数据库查阅表柔比星、环磷酰胺致肺病案例,分析患者不良反应特点及治疗经过。结果:临床药师参考文献资料,建议医师暂停患者全身化疗,并经呼吸科专家会诊,给予泼尼松治疗,患者间质性肺病缓解。结论:临床药师应对恶性肿瘤患者加强药学监护,及时发现药物导致的不良反应,并参考文献资料,提出合理化建议,保障患者用药安全、有效。
Objective:To provide reference for the safe use of epirubicin and cyclophosphamide(EC)regimen in cancer patients.Methods:A clinical pharmacist participated in the treatment of a patient with rare grade 2 interstitial pneumonia evaluated on CTCAE caused by EC regimen,and collected cases of lung injury caused by epirubicin and cyclophosphamide from databases such as PubMed,Elsevier Science Direct,China National Knowledge Infrastructure,and Wanfang.The characteristics of adverse reactions and their treatment were analyzed.Results:The clinical pharmacist recommended after referring to the literature and consultation with a respiratory specialist that the physician would temporarily suspend her systemic chemotherapy and give her prednisone treatment.Her drug-induced interstitial pneumonia was relieved by this way.Conclusion:Clinical pharmacists should strengthen pharmaceutical monitoring for patients with malignant tumors,promptly identify adverse reactions caused by drugs,and provide rational recommendations based on literature to ensure the safe and effective use of drugs for patients.
作者
孙慧慧
方英立
王向玲
李际盛
SUN Huihui;FANG Yingli;WANG Xiangling;LI Jisheng(Department of Clinical Pharmacy,Qilu Hospital of Shandong University,Ji’nan 250012,China;Department of Pharmacy,Pingyi People’s Hospital,Linyi 276000,China;Department of Oncology,Qilu Hospital of Shandong University,Ji’nan 250012,China)
出处
《上海医药》
CAS
2024年第13期69-71,I0003,共4页
Shanghai Medical & Pharmaceutical Journal
关键词
间质性肺病
表柔比星
环磷酰胺
药学监护
interstitial pneumonia
epirubicin
cyclophosphamide
pharmaceutical care
